Podiumcast

Login Create Account

Login Create an Account

AsMA Annual Scientific Meeting

Reno, NV

May 23, 2022 - May 26, 2022

Best Value!

Full Library Package

$159.00

Includes Lifetime Online Access To All Listed Sessions!

All Sessions

(81)

Session Title	Format	Price
67TH LOUIS H. BAUER LECTURE "Historical Issues in U.S. Aerospace Medicine: What did we know? When did we know it? Could we have predicted it?” Learn more 67TH LOUIS H. BAUER LECTURE "Historical Issues in U.S. Aerospace Medicine: What did we know? When did we know it? Could we have predicted it?” Speaker(s): Session Description: Product Format: Synced Video with Speaker Media Type: Streamable Media Format Description: Audio Synced with Slides + Video of Speaker Stream or Download 202204100	Synced Video with Speaker	$20.00
ERIC P. KINDWALL MEMORIAL LECTURE “Decision Making for Hyperbaric Oxygen for Brain Injury” Learn more ERIC P. KINDWALL MEMORIAL LECTURE “Decision Making for Hyperbaric Oxygen for Brain Injury” Speaker(s): Lindell Weaver, M.D. Session Description: Product Format: Synced Video with Speaker Media Type: Streamable Media Format Description: Audio Synced with Slides + Video of Speaker Stream or Download 202204101	Synced Video with Speaker	$20.00
[S-04]: PANEL: UNDERSTANDING AND MODIFYING INTRACRANIAL PRESSURE, RESULTS OF A RANDOMISED CONTROL TRIAL MAY HAVE NOVEL IMPLICATIONS FOR SPACEFLIGHT Learn more [S-04]: PANEL: UNDERSTANDING AND MODIFYING INTRACRANIAL PRESSURE, RESULTS OF A RANDOMISED CONTROL TRIAL MAY HAVE NOVEL IMPLICATIONS FOR SPACEFLIGHT Speaker(s): Chair: Susan Mollan Session Description: PANEL OVERIVEW: Raised intracranial pressure (ICP) has the potential to cause significant morbidity and mortality in a range of conditions including idiopathic intracranial hypertension (IIH), traumatic brain injury (TBI) and spaceflight associated neuro-ocular syndrome (SANS). The full consequences of SANS are not yet comprehensively determined and cannot be reliably predicted, particularly in those undergoing longer duration space missions (>3 months). In those with SANS and prolonged optic nerve oedema of any cause there is a significant risk of visual loss. This loss can be permanent, as seen in patients with IIH. The medications currently used for raised ICP are not well tolerated, and indeed likely contraindicated for long-term use in space medicine. There are no current treatments or countermeasures for SANS. There are also wide-reaching consequences of elevated ICP, for example raised ICP affects cognitive performance acutely and in the longer term in people with IIH. This might also be a consideration in astronauts, where there may be the potential to impair performance. This panel will report the findings of the first human randomised control trial utilising telemetric, intraparenchymal ICP monitors to investigate the biological effect of a Glucagon-like Peptide 1 receptor agonist (GLP1-RA) on ICP in a cohort of participants with IIH: the IIH:Pressure study. Our pre-clinical work has demonstrated that the incretin, Exenatide, GLP-1RA, can cross the blood-brain-barrier and reduces cerebrospinal fluid secretion and consequently lowered ICP by 43% in vivo. Exenatide is an established 2:00 PM drug, widely used to treat diabetes, with a favourable side effect profile. Hypoglycaemia does not occur with GLP-1RA administration. The associated studies of IIH:physiology and IIH:Pressure Medicine, will also be presented here. The importance of how ICP behaves in a raised ICP human model is invaluable, where we have gained new insights into both the physiology and the impact on cognitive performance. By providing evidence of a direct effect of drug therapies on ICP and cognition will allow physicians to select optimal treatment options when faced with raised ICP. The impact of SANS on astronaut health is a growing concern. Spaceflight duration is anticipated to increase, particularly in the context of missions to Mars and spaceflight commercialisation. A well tolerated therapy reducing ICP would be beneficial to alleviate SANS and the associated long-term sequelae. Product Format: Synced Video Media Type: Streamable Media Format Description: Audio Synced with Speaker Slides as MP4 Video A precise capture of how the session transpired. Crystal-clear audio synced with PowerPoint including slide transitions, animation, embedded video. May include additional materials if available. 202204102	Synced Video	$20.00
[S-05]: PANEL: RIDING THE COVID-19 WAVE: A MULTI-DISCIPLINARY PANEL ON LATEST DATA ON COVID-19 IN US AIR FORCE AIRCREW Learn more [S-05]: PANEL: RIDING THE COVID-19 WAVE: A MULTI-DISCIPLINARY PANEL ON LATEST DATA ON COVID-19 IN US AIR FORCE AIRCREW Speaker(s): Chair: Dara Regn Session Description: PANEL OVERIVEW: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as COVID-19, is a highly infectious, rapidly progressive predominantly respiratory disease, with multi-organ involvement. The United States Air Force has not been immune to the adverse impact of increased rates of COVID-19 infection with over 42K* active duty, guard and reserve members having had documented cases. The special physical requirements for aviators and the potential complications associated with aviation will in many cases necessitate additional evaluation for members who have had COVID-19. Based upon the medical literature, the USAF Aeromedical Consult Service (ACS) in conjunction with USAF Medical Readiness Agency (AFMRA) compiled comprehensive return-to-flying-status recommendations based on COVID-19 severity and crew position. Aeromedical concerns include the potential for cardiac complications such as myocarditis, as well as pulmonary complications resulting in inadequate lung ventilation in relation to exercise level and increased breathing resistance attributable to weak respiratory muscles, which in turn, result in a corresponding increased risk of hypoxia and hypercapnia. Additional safety-related concerns and longer-term sequelae which may interfere with performance of duties include neurologic and psychiatric sequelae such as olfactory dysfunction, “brain fog,” poor sleep quality, depression, anxiety, and fatigue. The USAF ACS resumed in-person medical evaluations in June 2020, to include pilot applicant screening and return–to-flying-status waiver evaluations. Since that time, >1000 initial pilot applicants were seen and of those approximately 210 have had documented history of COVID-19 with numbers steadily increasing. Pilot applicants with a history of COVID undergo evaluation which includes full pulmonary function testing, 6 MWT, ECG, Holter monitoring, troponin, and echocardiogram. Thus far, ~8% of applicants post COVID were found to have disqualifying findings on pulmonary or cardiac evaluation potentially attributable to COVID sequelae (data collection and analysis is ongoing). In this panel we will discuss the return-to-flying-status recommendations, medical evaluation data and aircrew case studies from Pulmonary, Cardiology, Psychiatry and Neurology aeromedical perspectives. Data 27 SEPT 21 Product Format:* Non-Synced Audio/Presentation Podcast Media Type: Streamable Media Format Description: Audio + Speaker Presentation Materials MP3 audio of the entire session including Q and A. May include Presentation materials in PDF format if available. 202204103	Non-Synced Audio/Presentation Podcast	$20.00
[S-06]: SLIDES: LIFE IN THE FAST LANE: ACCELERATION EFFECTS Learn more [S-06]: SLIDES: LIFE IN THE FAST LANE: ACCELERATION EFFECTS Speaker(s): Chair: Joseph Hudson Session Description: Product Format: Non-Synced Audio/Presentation Podcast Media Type: Streamable Media Format Description: Audio + Speaker Presentation Materials MP3 audio of the entire session including Q and A. May include Presentation materials in PDF format if available. 202204104	Non-Synced Audio/Presentation Podcast	$20.00